ongitudinal analysis of lung cancer-specific immunity in stage III and IV non-small cell lung cancer patients.
Recruiting
- Conditions
- Histologically or cytologically proven irresectable stage III or IV non-small cell lung cancer
- Registration Number
- NL-OMON25535
- Lead Sponsor
- Stichting Het Nederlands Kanker Instituut - Antoni van Leeuwenhoek ZiekenhuisAmsterdam, The Netherlands
- Brief Summary
/A
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Not specified
- Target Recruitment
- 50
Inclusion Criteria
1. Histologically or cytologically proven irresectable stage III or IV non-small cell lung cancer;
2. Age above 18 years;
Exclusion Criteria
1. Severe anemia (Hb < 6.0 mmol/L);
2. Any bleeding disorder or anti-coagulation therapy, that cannot be discontinued or corrected, that significantly increases the risk of a bleeding due to the biopsy.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method